Healthcare Business

Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?

Neurotrope Inc. (NASDAQ: NTRP) may be a winner by default in the battle against Alzheimer's disease after shares of Biogen Inc. (NASDAQ: BIIB) suffered handily with the announcement that it ...
Read Full Story »

Why This Alzheimer’s Study Is Crushing Biogen Shares

Biogen Inc. (NASDAQ: BIIB) shares were crushed in Thursday’s session after the firm announced that it would be discontinuing its late-stage trial for Alzheimer’s disease. Specifically, the firm is discontinuing ...
Read Full Story »

Why Pfizer Is Getting Deeper Into Gene Therapy

Pfizer Inc. (NYSE: PFE) is getting deeper into gene therapy. The U.S. drug giant has acquired a 15% stake in Vivet Therapeutics. On top of the investment in the French ...
Read Full Story »

Pfizer Moves Over Half a Billion for Wilson Disease Treatment

Pfizer Inc. (NYSE: PFE) has announced that it has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer is looking to ...
Read Full Story »

Bad News for AbbVie and Multiple Myeloma Patients

AbbVie Inc. (NYSE: ABBV) and patients suffering from multiple myeloma have seen some additional bad news. The Food and Drug Administration (FDA) has placed a partial clinical hold on clinical ...
Read Full Story »

America’s Unsafe Medical Products

The U.S. Food and Drug Administration (FDA) has announced four new voluntary recalls for three drugs and one medical device. The agency also released an update on an earlier notification ...
Read Full Story »

What’s Next for Altimmune’s Influenza Vaccine

Positive results from a midstage influenza study sent Altimmune Inc. (NASDAQ: ALT) shares sharply higher on Tuesday. Specifically, the positive data came from the firm’s Phase 2 extension study of ...
Read Full Story »

Dermira’s Eczema Treatment Lebrikizumab Breaks Through

Dermira Inc. (NASDAQ: DERM) shares more than doubled on Monday after the firm announced midstage results from its eczema study. Specifically, Dermira announced positive results from its Phase 2b dose-ranging ...
Read Full Story »

What Its Antiplatelet Reversal Agent Means for PhaseBio Going Forward

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) shares more than doubled on Monday after the firm released results from an early-stage clinical trial. The results were published online in the New England ...
Read Full Story »

5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of ...
Read Full Story »

Can Karyopharm’s Myeloma Treatment Selinexor Pass Muster?

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares jumped on Friday after the firm announced an update from the U.S. Food and Drug Administration (FDA). Specifically, the FDA has extended the Prescription ...
Read Full Story »

How Much More Talc Fallout Will Johnson & Johnson Face After This $29 Million Verdict?

A California jury has awarded $29 million to a woman who claimed talcum-powder-based Johnson & Johnson (NYSE: JNJ) products caused her cancer. This ruling is the most recent defeat, out of ...
Read Full Story »

Vadadustat Makes the Case for Blockbuster Status After Japanese Chronic Kidney Disease Studies

Patients suffering anemia due to chronic kidney disease (CKD) are sure to be content with new positive top-line results from two Phase 3 active-controlled pivotal studies. In this case, they ...
Read Full Story »

Major Biotechs See a Rising Tide in Short Interest

The short interest data are out for the most recent settlement date, February 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Big Pharma Short Interest Backs Off, With One Huge Exception

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »